CliffBio
small molecule

NEXTERONE

AMIODARONE HYDROCHLORIDE

Loss of exclusivityFebruary 2033latest FDA-listed patent expiry
CompanyBaxter Healthcare Corp →View the full company profile on CliffBio

Drug detail

Brand nameNEXTERONE
Active ingredientAMIODARONE HYDROCHLORIDE
Strength150MG/100ML (1.5MG/ML)
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalNovember 2010
Marketing statusRX

Listed patents

PatentExpiresType
9493582February 2033product
10117951March 2029product
8410077March 2029product
7635773March 2029product
9200088March 2029product
9750822March 2029product
10177951March 2029product

More from Baxter Healthcare Corp

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NEXTERONE patent cliff — loss of exclusivity February 2033 | CliffBio